$Quoin Pharmaceuticals (QNRX.US)$ Quoin Pharmaceuticals (NASDAQ: QNRX) has announced pricing of a $6.8 million public offering, consisting of 15,111,110 ordinary shares represented by ADSs (or pre-funded warrants) at $0.45 per ADS. The offering includes Series F and G warrants to purchase up to 15,111,110 ADSs each, with exercise prices of $0.45 per share and expiration periods of 2 and 5 years respectively.
The company plans to use proceeds for general corporate purposes, including operating expenses, R&D, clinical testing, working capital, and potential acquisitions. The offering, which includes participation from executives and directors, is expected to close around December 23, 2024. Additionally, Quoin has modified certain existing warrants, reducing their exercise price from $1.60 to $0.45 per ADS and extending their expiration to December 2029.